Theravance Biopharma Inc (NASDAQ: TBPH) stock suffered a major decline of -18.4% on 8/6/24. The shares closed at $7.83. Moreover, this decline was accompanied by exceptionally high trading volume at 515% of normal. The stock has been weak relative to the market over the last nine months and has declined -22.6% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, TBPH is expected to be a Value Builder.
Theravance Biopharma has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing highly consistent signals. Theravance Biopharma has a poor Power Rating of 28 and a poor Appreciation Score of 23, and the Lowest Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment